Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 5/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 4/20 | 0.49 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20594709 | 0.87 | TGM2 (0.51) | PDPK1ALDH1A1AURKARAF1TGM2 | |
| SCHEMBL30183643 | 0.87 | TGM2 (0.51) | PDPK1ALDH1A1AURKARAF1TGM2 | |
| SCHEMBL10061664 | 0.84 | PDPK1 (0.55) | PDPK1ALDH1A1AURKARAF1CASP3 | |
| SCHEMBL9113250 | 0.83 | CA12 (0.50) | ALDH1A1TGM2SMYD3CES1CA12 | |
| SCHEMBL3052163 | 0.82 | PDPK1 (0.53) | PDPK1ALDH1A1AURKARAF1CASP3 | |
| Hydrochloric Acid SCHEMBL11430193 | 0.82 | CA12 (0.49) | ALDH1A1TGM2SMYD3CES1CA12 | |
| SCHEMBL21440350 | 0.81 | PDPK1 (0.50) | PDPK1AURKARAF1CASP3TDP1 | |
| SCHEMBL23252156 | 0.80 | PDPK1 (0.51) | PDPK1ALDH1A1AURKARAF1CASP3 | |
| SCHEMBL5894451 | 0.80 | PDPK1 (0.63) | PDPK1ALDH1A1AURKARAF1TGM2 | |
| SCHEMBL5894610 | 0.80 | PDPK1 (0.63) | PDPK1ALDH1A1AURKARAF1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099438-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-03-27 | — | — | US | disclosed |
| US-12194027-B2 | Small molecule inhibitors of GPCR GPR68 and related receptors for treating cancer, glioblastoma, and other indications | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240327364-A1 | THERAPEUTIC TARGETING OF GPR68 TO INDUCE FERROPTOSIS | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-10-03 | — | — | US | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20220202785-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| US-20220202785-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| US-11370779-B2 | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | Pelemed Co., Ltd. (KR) | 2022-06-28 | — | — | US | disclosed |
| EP-3955922-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS | University of Maryland, Baltimore (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020214896-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020214896-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20200270229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER | Pelemed Co., Ltd. (KR) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER | FLT3, ABL1, MCL1 | PDPK1 1558/4885ALDH1A1 1640/4885AURKA 80/4885 |
| US-20240327364-A1 | THERAPEUTIC TARGETING OF GPR68 TO INDUCE FERROPTOSIS | GPR68, GPR65, GPR84 | PDPK1 512/4885ALDH1A1 3482/4885AURKA 1543/4885 |
| US-20250099438-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | GPR68, GPR65, GPR4 | PDPK1 1790/4885ALDH1A1 4359/4885AURKA 2371/4885 |
| US-12194027-B2 | Small molecule inhibitors of GPCR GPR68 and related receptors for treating cancer, glioblastoma, and other indications | GPR68, GPR65, GPR4 | PDPK1 1790/4885ALDH1A1 4359/4885AURKA 2371/4885 |
| US-20220202785-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | GPR68, GPR65, GPR4 | PDPK1 1790/4885ALDH1A1 4359/4885AURKA 2371/4885 |
| US-11370779-B2 | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | FLT3, ABL1, MCL1 | PDPK1 1558/4885ALDH1A1 1640/4885AURKA 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.